New Mexico Cancer Care Alliance
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://nmcca.org
Compassionate Use of BYL 719 Alpelisib
- Conditions
- Lymphangioma
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- New Mexico Cancer Care Alliance
- Registration Number
- NCT03941782
- Locations
- 🇺🇸
University of New Mexico - Cancer Center, Albuquerque, New Mexico, United States
Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging
- Conditions
- HER2 Negative Breast Cancer
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- New Mexico Cancer Care Alliance
- Target Recruit Count
- 30
- Registration Number
- NCT03568448
- Locations
- 🇺🇸
University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
Whole Brain Radiation Using IMRT for Patients With Brain Metastases
- Conditions
- Central Nervous System MetastasesNeoplasm Metastasis
- Interventions
- Radiation: Intensity Modulated Radiotherapy
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- New Mexico Cancer Research Alliance
- Target Recruit Count
- 29
- Registration Number
- NCT02753790
- Locations
- 🇺🇸
Universtiy of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- New Mexico Cancer Care Alliance
- Registration Number
- NCT02720601
- Locations
- 🇺🇸
Universtiy of New Mexico - Cancer Center, Albuquerque, New Mexico, United States
Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses
- Conditions
- Leukemia, Acute Lymphoblastic
- Interventions
- Other: Acute Lymphobastic Leukemia (ALL) Treatment Options
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- New Mexico Cancer Care Alliance
- Target Recruit Count
- 21
- Registration Number
- NCT02580981
- Locations
- 🇺🇸
University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
- Conditions
- Fallopian Tube CancerPeritoneal NeoplasmsOvarian Cancer
- Interventions
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- New Mexico Cancer Care Alliance
- Target Recruit Count
- 50
- Registration Number
- NCT02571725
- Locations
- 🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States
🇺🇸Southwest Gynecologic Oncology Associates, Albuquerque, New Mexico, United States
🇺🇸University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
- Conditions
- Ovarian CancerFallopian Tube CancerPeritoneal Cancer
- Interventions
- Other: PlaceboDrug: Ketorolac
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- New Mexico Cancer Care Alliance
- Target Recruit Count
- 21
- Registration Number
- NCT02470299
- Locations
- 🇺🇸
Universtiy of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
- Conditions
- Oropharyngeal Cancer
- First Posted Date
- 2014-05-26
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- New Mexico Cancer Care Alliance
- Target Recruit Count
- 30
- Registration Number
- NCT02147418
- Locations
- 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
Genome Sequencing of Human Cancer Tissues
- Conditions
- Cancer
- Interventions
- Other: Cancer Treatment Options
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- New Mexico Cancer Care Alliance
- Target Recruit Count
- 250
- Registration Number
- NCT02105545
- Locations
- 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- Drug: Combination therapy
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2015-07-31
- Lead Sponsor
- New Mexico Cancer Care Alliance
- Target Recruit Count
- 1
- Registration Number
- NCT01889420
- Locations
- 🇺🇸
UNM Cancer Research and Treatment Center, Albuquerque, New Mexico, United States